fbpx

ONCOLOGY PRODUCTS

ColoPlex Adjunct

Status: CE Marked for Sales outside the US

CRC is the most common newly diagnosed cancer and is the second most cause of cancer deaths.

ColoPlex Plus

Status: In Development

A simple blood test to detect early risk of colorectal cancer. Patients are more likely to participate in CRC screening programs when a blood test is offered compared to a fecal test.

ColoHealth

Status: Piloting Launch

A molecular test that detects Methylated Septin 9 DNA in Blood. Methylated Septin 9 tumor DNA is shed into the bloodstream and displays a unique methylation pattern that is detectable in plasma by Real-Time PCR.

PROCARE

Status: In Development

This technology has the potential to be more accurate than other common prostate cancer markers in detecting and monitoring prostate cancer, as well as guiding therapy.